Compare NBY & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBY | PHGE |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3M | 6.9M |
| IPO Year | 2007 | N/A |
| Metric | NBY | PHGE |
|---|---|---|
| Price | $1.07 | $4.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $26.00 |
| AVG Volume (30 Days) | ★ 116.4K | 62.5K |
| Earning Date | 11-07-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $10,302,000.00 | N/A |
| Revenue This Year | $23.91 | N/A |
| Revenue Next Year | $32.05 | N/A |
| P/E Ratio | $41.19 | ★ N/A |
| Revenue Growth | ★ 390.34 | N/A |
| 52 Week Low | $0.46 | $4.10 |
| 52 Week High | $4.44 | $22.06 |
| Indicator | NBY | PHGE |
|---|---|---|
| Relative Strength Index (RSI) | 48.92 | 74.68 |
| Support Level | $1.00 | $4.10 |
| Resistance Level | $1.11 | $4.91 |
| Average True Range (ATR) | 0.09 | 0.30 |
| MACD | 0.02 | 0.39 |
| Stochastic Oscillator | 84.28 | 77.56 |
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).